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Correction to: Nature Communications https://doi.org/10.1038/s41467-018-04711-w, published online 11 Jun 2018.
In the original version of this Article, references in the Methods section incorrectly referred to references in the Supplementary
References section. The relevant references (now numbered 20, 27, 42, 47, 69–80) have been removed from the Supplementary
References section of the Supplementary Information ﬁle and added to the References section of the main manuscript, in both the PDF
and HTML versions of the Article.
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and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit
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you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
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